Table 2.

Univariate analysis of different prognostic factors in patients treated with regorafenib.

Item	PFS (mo) (95% CI)	P-value	OS (mo) (95% CI)	P-value
Age, y
⩽65	2.8 (2.5-3.3)	.599	7.9 (6.0-9.7)	.628
>65	2.95 (0.4-NR)		8.1 (3.2-NR)
Gender
Male	3.0 (2.5-3.8)	.139	8.0 (6.0-13.1)	.986
Female	2.6 (2.3-3.0)		7.9 (5.3-12.8)
ECOG PS
1	3.3 (2.6-4.6)	.0002	8.6 (6.7-14)	.010
>1	2.3 (1.7-3.0)		5.4 (4.2-7.9)
Interval from metastasis to regorafenib
⩽12 mo	3.8 (1.7-NR)	.394	6.6 (2.9-NR)	.537
>12 mo	2.7 (2.5-3.1)		8.1 (6-12)
Sidedness of primary tumor
Right	2.9 (2.3-3.3)	.764	9.3 (5.1-14.4)	.860
Left	2.8 (2.4-3.6)		8.0 (6.0-11.4)
Number of organs involved
1	2.4 (2.0-2.9)	.081	9.3 (5.1-15.2)	.633
>1	3.0 (2.5-3.7)		7.9 (5.8-11.4)
Liver metastasis
Yes	2.8 (2.5-3.3)	.328	7.9 (5.8-9.3)	.442
No	2.6 (1.8-4.6)		12.8 (5.1-15.2)
KRAS gene mutation
Wild	2.9 (2.1-3.8)	.995	8.1 (5.4-17.3)	.311
Mutant	2.8 (2.5-3.3)		6.4 (5.3-9.7)
Prior bevacizumab
Yes	2.8 (2.5-3.3)	.972	8 (6.0-9.7)	.658
No	2.8 (2.0-5.3)		6.6 (3.2-NR)
Prior cetuximab
Yes	2.9 (2.0-7.4)	.280	8.1 (5.4-15.2)	.973
No	2.8 (2.5-3.3)		8.0 (5.8-12.8)
Regorafenib starting dose
160 mg	2.3 (2.1-3.3)	.547	12.8 (5.1-18.1)	.149
<160 mg	3.0 (2.6-3.7)		6.6 (5.4-8.6)
Dose reduction
Yes	3.0 (2.6-3.8)	.0012	8.0 (6.2-11.4)	.573
No	2.2 (2.0-2.5)		6.0 (4.1-13.1)

Abbreviations: CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; NR, not reached; OS, overall survival; PFS, progression-free survival.